Earnings call transcript: Cardinal Health Q4 2025 misses revenue forecast

Cardinal Health (CAH) reported mixed Q4 2025 results, with earnings per share of $2.08 surpassing the $2.03 forecast, but revenue of $60.2 billion missing the $60.92 billion estimate. This revenue shortfall triggered an 11.58% pre-market stock decline, despite a 19% increase in operating earnings and a raised fiscal 2026 EPS guidance to $9.30-$9.50, projecting 13-15% growth. The company emphasized strategic acquisitions like Solaris Health and continued innovation, alongside strong free cash flow generation and an 'undervalued' assessment by InvestingPro, indicating that immediate investor concerns over the revenue miss may overshadow a fundamentally strong operational performance and positive future outlook.

Analysis

Cardinal Health's Q4 2025 results present a clear dichotomy between a top-line miss and strong underlying profitability, triggering a significant negative market reaction. The company reported a 1.18% revenue shortfall at $60.2 billion against a $60.92 billion forecast, causing an 11.58% pre-market stock decline. However, this overshadows robust operational performance, including a 19% year-over-year increase in operating earnings to $719 million and an EPS of $2.08, which beat estimates by 2.46%. The company's strategic pivot towards higher-margin segments is accelerating, evidenced by the acquisition of Solaris Health to bolster its specialty alliances and strong performance in its growth businesses, which contributed over 40% of enterprise operating earnings growth. Management's confidence is underscored by a raised fiscal 2026 EPS guidance to $9.30-$9.50, projecting 13-15% growth. Coupled with data suggesting the stock is undervalued, including a low PEG ratio of 0.16, the market's immediate focus on the revenue figure may disregard strengthening fundamentals and a clear strategy for future value creation.

Key Decisions for Investors

• Investors should assess whether the 11.58% stock decline, driven by a modest 1.18% revenue miss, represents an overreaction given the firm's 19% growth in operating earnings and positive EPS surprise.
• The strategic pivot towards higher-margin specialty businesses via acquisitions like Solaris Health and the strong outlook for its growth segments, projected to grow 26-28%, warrant close attention as primary drivers of future value.
• Consider the forward-looking guidance, with projected EPS growth of 13-15% for fiscal 2026 and a PEG ratio of 0.16, which suggests the current pullback may offer a favorable entry point for those with a long-term investment horizon.